Sana Biotechnology, Inc.
https://sana.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sana Biotechnology, Inc.
Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1
Public Company Edition: Fourth quarter 2023 fundraising fell 25.1% from Q4 2022, including a 24.2% drop in follow-on dollars, but recent activity has been robust, including $300m and $350m offerings by 4DMT and Autolus. Also, BMS sold $13bn in notes to fund Karuna and RayzeBio deals.
Sana Lifted By Allo-CAR-T Data, Moves Ahead Into Autoimmune Disease
Sana claims to has cracked one of allo-CAR-Ts biggest challenges, blocking NK cells from destroying the therapies, and for now, investors are impressed.
AbbVie Looks To Umoja To Partner On In Vivo CAR-Ts
Umoja’s technology is meant to enable development of CAR-Ts that could potentially overcome the challenges associated with autologous cell therapies, especially related to manufacturing.
Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation
CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice